MARKET

DRRX

DRRX

DURECT
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.4451
-0.0192
-4.14%
Opening 15:34 07/06 EDT
OPEN
0.4600
PREV CLOSE
0.4643
HIGH
0.4760
LOW
0.4400
VOLUME
379.22K
TURNOVER
109.78K
52 WEEK HIGH
1.610
52 WEEK LOW
0.3601
MARKET CAP
101.38M
P/E (TTM)
-2.7391
1D
5D
1M
3M
1Y
5Y
Durect names ex-RBC Capital Markets executive as CFO
Durect (NASDAQ:DRRX) <a href="https://seekingalpha.com/pr/18854927-du...
Seekingalpha · 1d ago
Durect Says Timothy Papp Named Chief Financial Officer
MT Newswires · 1d ago
What Kind Of Shareholders Hold The Majority In DURECT Corporation's (NASDAQ:DRRX) Shares?
A look at the shareholders of DURECT Corporation ( NASDAQ:DRRX ) can tell us which group is most powerful. Institutions...
Simply Wall St. · 06/18 12:05
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Investor Place · 06/09 11:26
Health Check: How Prudently Does DURECT (NASDAQ:DRRX) Use Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Simply Wall St. · 05/31 10:21
Executives Buy Around $17M Of 5 Penny Stocks
The Nasdaq Composite index tumbled by more than 550 points on Wednesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors...
Benzinga · 05/19 13:03
DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference
DURECT Corporation (Nasdaq: DRRX) today announced that Dr. James E. Brown, President and CEO, Dr. Norman Sussman, Chief Medical Officer, and Dr. WeiQi Lin, Executive Vice President of R&D, will be participating in a fireside chat hosted by Ed Arce, Managin...
PR Newswire · 05/18 17:53
DURECT Corporation (NASDAQ:DRRX) Just Reported Earnings, And Analysts Cut Their Target Price
Shareholders might have noticed that DURECT Corporation ( NASDAQ:DRRX ) filed its quarterly result this time last week...
Simply Wall St. · 05/08 12:19
More
No Data
Learn about the latest financial forecast of DRRX. Analyze the recent business situations of DURECT through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

33.33%Strong Buy
66.67%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average DRRX stock price target is 5.67 with a high estimate of 6.00 and a low estimate of 5.00.
High6.00
Average5.67
Low5.00
Current 0.4451
EPS
Actual
Estimate
-0.04-0.03-0.02-0.01
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 142
Institutional Holdings: 144.86M
% Owned: 63.60%
Shares Outstanding: 227.76M
TypeInstitutionsShares
Increased
17
2.22M
New
11
666.02K
Decreased
33
2.17M
Sold Out
14
780.85K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.54%
Pharmaceuticals & Medical Research
+0.66%
Key Executives
Non-Executive Chairman/Independent Director
David Hoffmann
President/Chief Executive Officer/Director
James Brown
Senior Vice President
Judy Joice
Chief Accounting Officer
Jian Li
Other
Norman Sussman
Director
Gail Farfel
Independent Director
Mohammad Azab
Independent Director
Terrence Blaschke
Independent Director
Peter Garcia-Webb
Independent Director
Gail Maderis
Independent Director
Judith Robertson
No Data
No Data
About DRRX
DURECT Corporation is a biopharmaceutical company that is focused on advancing lifesaving investigational therapies. The Company's product candidates include DUR-928 oral for metabolic/lipid disorders, and DUR-928, injectable for acute organ injuries. The Company’s other commercial product candidates include POSIMIR, PERSERIS and Methydur Sustained Release Capsules. The Company is conducting a Phase IIb study (AHFIRM) of larsucosterol (DUR-928) in subjects with severe alcohol-associated hepatitis (Alcoholic Hepatitis (AH) to evaluate the safety and efficacy of larsucosterol treatment. Larsucosterol (DUR-928) is lead product candidate, an endogenous sulfated oxysterol and an epigenetic regulator. The Company focuses on drug delivery technology around its SABER and CLOUD Bioerodible Injectable Depot Systems. SABER uses a high viscosity base component, such as sucrose acetate isobutyrate (SAIB), to provide controlled release of a drug.

Webull offers kinds of DURECT Corporation stock information, including NASDAQ:DRRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DRRX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading DRRX stock methods without spending real money on the virtual paper trading platform.